IL272924A - שיטות להכנה ולשימוש באנדוקסיפן - Google Patents

שיטות להכנה ולשימוש באנדוקסיפן

Info

Publication number
IL272924A
IL272924A IL272924A IL27292420A IL272924A IL 272924 A IL272924 A IL 272924A IL 272924 A IL272924 A IL 272924A IL 27292420 A IL27292420 A IL 27292420A IL 272924 A IL272924 A IL 272924A
Authority
IL
Israel
Prior art keywords
endoxifen
making
methods
Prior art date
Application number
IL272924A
Other languages
English (en)
Other versions
IL272924B2 (he
IL272924B1 (he
Original Assignee
Atossa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65635248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL272924(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atossa Therapeutics Inc filed Critical Atossa Therapeutics Inc
Publication of IL272924A publication Critical patent/IL272924A/he
Publication of IL272924B1 publication Critical patent/IL272924B1/he
Publication of IL272924B2 publication Critical patent/IL272924B2/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10Separation; Purification; Stabilisation; Use of additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dental Preparations (AREA)
  • Primary Cells (AREA)
  • Paper (AREA)
  • Catalysts (AREA)
IL272924A 2017-09-11 2018-09-10 שיטות להכנה ולשימוש באנדוקסיפן IL272924B2 (he)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762556884P 2017-09-11 2017-09-11
US201762556799P 2017-09-11 2017-09-11
US201862624787P 2018-01-31 2018-01-31
US201862693885P 2018-07-03 2018-07-03
PCT/US2018/050272 WO2019051416A1 (en) 2017-09-11 2018-09-10 METHODS FOR THE MANUFACTURE AND USE OF ENDOXIFEN

Publications (3)

Publication Number Publication Date
IL272924A true IL272924A (he) 2020-04-30
IL272924B1 IL272924B1 (he) 2023-09-01
IL272924B2 IL272924B2 (he) 2024-01-01

Family

ID=65635248

Family Applications (2)

Application Number Title Priority Date Filing Date
IL304863A IL304863A (he) 2017-09-11 2018-09-10 שיטות להכנה ולשימוש באנדוקסיפן
IL272924A IL272924B2 (he) 2017-09-11 2018-09-10 שיטות להכנה ולשימוש באנדוקסיפן

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL304863A IL304863A (he) 2017-09-11 2018-09-10 שיטות להכנה ולשימוש באנדוקסיפן

Country Status (12)

Country Link
US (4) US11261151B2 (he)
EP (1) EP3681491A4 (he)
JP (2) JP2020533283A (he)
KR (1) KR20200052349A (he)
CN (2) CN111328280A (he)
AU (2) AU2018329202B2 (he)
CA (1) CA3073836A1 (he)
IL (2) IL304863A (he)
MX (1) MX2020002649A (he)
SG (1) SG11202002105WA (he)
TW (1) TWI793165B (he)
WO (1) WO2019051416A1 (he)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018329202B2 (en) 2017-09-11 2022-10-27 Atossa Therapeutics, Inc. Methods for making and using endoxifen
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CN110564962B (zh) * 2019-10-14 2020-12-22 中南大学 一种黑白钨混合矿的冶炼方法
CN113975279A (zh) * 2021-10-13 2022-01-28 复旦大学附属肿瘤医院 维拉佐酮及其衍生物在制备抗肿瘤药物中的应用
IL314075A (he) * 2022-01-12 2024-09-01 Atossa Therapeutics Inc הרכבים של (z)-אנדוקסיפן ושיטות להעשרתם
WO2023211939A1 (en) * 2022-04-26 2023-11-02 Atossa Therapeutics, Inc. High dose endoxifen formulations and methods of use

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
EP0168175B1 (en) 1984-06-12 1987-11-19 National Research Development Corporation Preparation of tamoxifen
GB8604528D0 (en) 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6398765B1 (en) 1999-03-01 2002-06-04 Pro Duct Health, Inc. Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
US6416981B1 (en) 2000-05-23 2002-07-09 Nec Partnership Production of gluconate salts
EP2050443B1 (en) 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
NZ540494A (en) 2002-12-18 2007-05-31 Besins Int Lab Treatment of mastalgia with 4-hydroxy tamoxifen
ES2456957T3 (es) 2003-04-01 2014-04-24 Besins Healthcare Luxembourg Sarl Tratamiento de cáncer de seno con 4-hidroxitamoxifen
EP1663142A2 (en) 2003-06-23 2006-06-07 MacroChem Corporation Compositons and methods for topical administration
US7531578B2 (en) 2003-09-18 2009-05-12 City Of Hope Compounds and methods for treating breast cancer and other diseases
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1709062B9 (en) 2004-01-16 2013-02-13 Cedarburg Pharmaceuticals, Inc. Exemestane and its intermediates and methods of making the same
US8436029B2 (en) 2004-03-19 2013-05-07 Transform Pharmaceuticals, Inc. Pharmaceutical forms, and methods of making and using the same
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20070059288A1 (en) 2005-03-31 2007-03-15 Dinsmore Jonathan H Treatment for heart disease
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
CA2608904A1 (en) 2005-07-06 2007-09-07 Sicor Inc. Improved process for the preparation of letrozole
CN102225046A (zh) 2005-08-05 2011-10-26 努沃研究公司 透皮释药剂型
CN101287454B (zh) 2005-10-12 2011-07-20 兴和株式会社 乳腺癌和/或乳腺炎治疗用离子电渗疗法制剂
WO2007067773A2 (en) 2005-12-09 2007-06-14 Mayo Foundation For Medical Education And Research Assessing outcomes for breast cancer patients by determining cyp2d6 genotype
JP5294874B2 (ja) 2005-12-20 2013-09-18 インサイト・コーポレイション インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロ環
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US8058302B2 (en) 2006-06-05 2011-11-15 Cadila Healthcare Limited Process for preparing pure anastrozole
CA2665105A1 (en) 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and its' process of preparation
US20120164075A1 (en) * 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
ES2665917T3 (es) 2006-11-21 2018-04-30 Jina Pharmaceuticals Inc. Endoxifeno para su uso en el tratamiento del cáncer
US20080207644A1 (en) 2006-11-27 2008-08-28 Sonis Stephen T Therapeutic materials and methods
WO2008067991A2 (en) 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
WO2008113177A1 (en) 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
CA2823407C (en) 2007-03-22 2016-10-18 Berg Pharma Llc Topical formulations having enhanced bioavailability
US20090068190A1 (en) 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
AR068409A1 (es) 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
EP2212301B1 (en) 2007-11-28 2012-02-29 Fresenius Kabi Oncology Limited An improved process for preparation of letrozole and its intermediates
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
US20100069781A1 (en) 2008-04-15 2010-03-18 Johansen Jerald A Device and method for accessing and treating ducts of mammary glands
US8063249B1 (en) 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
MY171866A (en) 2008-07-08 2019-11-05 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
EP2350111A1 (en) 2008-10-15 2011-08-03 Synthon B.V. Processes and intermediates for the production of fulvestrant
US20100098659A1 (en) 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
EP3656376A1 (en) 2008-12-11 2020-05-27 Besins Healthcare Luxembourg SARL Transdermal pharmaceutical compositions comprising a serm
CN103896786B (zh) * 2009-05-21 2015-11-25 扬子江药业集团有限公司 枸橼酸他莫昔芬的晶型及晶型a的制备方法
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US20120149761A1 (en) 2009-08-27 2012-06-14 Atossa Genetics, Inc. Nucleic acid molecules and uses thereof
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011072244A1 (en) 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
KR101308258B1 (ko) 2010-10-15 2013-09-13 씨제이제일제당 (주) 엔독시펜의 신규한 제조 방법
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
WO2012125445A2 (en) 2011-03-11 2012-09-20 President And Fellows Of Harvard College Small molecule-dependent inteins and uses thereof
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012162492A1 (en) 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
US9090640B2 (en) 2011-09-02 2015-07-28 Ulrich Bierbach Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
FR2980972B1 (fr) 2011-10-05 2014-02-28 Commissariat Energie Atomique Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes.
US9353132B2 (en) 2012-03-05 2016-05-31 Xavier University Of Louisiana Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
US9220680B2 (en) 2012-07-13 2015-12-29 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
WO2014060640A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
KR20150087400A (ko) 2012-11-20 2015-07-29 버텍스 파마슈티칼스 인코포레이티드 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물
CN113699114A (zh) 2013-02-26 2021-11-26 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
WO2014141292A2 (en) * 2013-03-04 2014-09-18 Intas Pharmaceuticals Limited Endoxifen citrate polymorph and process for preparing the same
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
TW201536278A (zh) * 2013-05-31 2015-10-01 Del Mar Pharmaceuticals 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途
CA2927752A1 (en) 2013-10-18 2015-04-23 The Regents Of The University Of Michigan Systems and methods for determining a treatment course of action
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015106094A1 (en) 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
EP3116488A4 (en) 2014-03-11 2018-04-25 Repros Therapeutics Inc. Clomiphene synthesis using a single solvent
JP6757935B2 (ja) 2014-06-04 2020-09-23 アトッサ ジェネティックス インク. 分子マンモグラフィ
CN104230723B (zh) 2014-08-21 2016-08-24 凯莱英医药集团(天津)股份有限公司 托瑞米芬的合成方法
EP3283061A4 (en) 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES
WO2016187122A1 (en) 2015-05-15 2016-11-24 University Of Iowa Research Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
AU2016294526A1 (en) 2015-07-14 2018-02-08 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
EP3365322B1 (en) * 2015-10-22 2021-05-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing (z)-endoxifen of high purity
DE102015222031A1 (de) * 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
US20170304232A1 (en) 2016-04-20 2017-10-26 Northwestern University Endoxifen For Local Transdermal Therapy To The Breast
AU2018329202B2 (en) * 2017-09-11 2022-10-27 Atossa Therapeutics, Inc. Methods for making and using endoxifen
WO2019051368A1 (en) 2017-09-11 2019-03-14 Atossa Genetics Inc. TOPICAL COMPOSITIONS
JP7376105B2 (ja) 2017-09-11 2023-11-08 アトッサ・セラピューティクス・インコーポレイテッド 局所用組成物及び処置方法

Also Published As

Publication number Publication date
US11680036B1 (en) 2023-06-20
US12071391B2 (en) 2024-08-27
US20200207704A1 (en) 2020-07-02
IL272924B2 (he) 2024-01-01
AU2018329202A1 (en) 2020-03-19
AU2018329202B2 (en) 2022-10-27
JP2020533283A (ja) 2020-11-19
KR20200052349A (ko) 2020-05-14
CA3073836A1 (en) 2019-03-14
AU2023200013B2 (en) 2024-09-12
WO2019051416A1 (en) 2019-03-14
JP2023126540A (ja) 2023-09-07
US20230183166A1 (en) 2023-06-15
US11261151B2 (en) 2022-03-01
SG11202002105WA (en) 2020-04-29
MX2020002649A (es) 2020-09-25
TWI793165B (zh) 2023-02-21
US20230365490A1 (en) 2023-11-16
CN116832020A (zh) 2023-10-03
TW201919596A (zh) 2019-06-01
US11572334B2 (en) 2023-02-07
EP3681491A4 (en) 2021-06-30
US20220242816A1 (en) 2022-08-04
IL272924B1 (he) 2023-09-01
AU2023200013A1 (en) 2023-02-09
IL304863A (he) 2023-10-01
CN111328280A (zh) 2020-06-23
EP3681491A1 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
PL3718370T3 (pl) Sposoby i powiązane urządzenia służące do realizacji funkcji multi-connectivity
SG11202002901TA (en) Structurally-colored articles and methods for making and using structurally-colored articles
GB201701109D0 (en) Method
GB201706778D0 (en) Method
GB201704847D0 (en) Callibration method
IL272924A (he) שיטות להכנה ולשימוש באנדוקסיפן
GB201805021D0 (en) Method and use
GB201805103D0 (en) Method and use
GB201805024D0 (en) Method and use
GB201805042D0 (en) Method and use
GB201706544D0 (en) Method
GB201700352D0 (en) Method
EP3720940C0 (en) PARTS WASHING PROCESS
GB201703036D0 (en) Methods
GB201702250D0 (en) Method
DK3615520T3 (en) Methods
GB201708853D0 (en) Method
GB201707140D0 (en) Method
GB201705897D0 (en) Method
GB201704536D0 (en) Method
GB201702096D0 (en) Method
GB201701941D0 (en) Method
SG11202000935SA (en) Cis-polycycloolefins and methods for forming cis-polycycloolefins
GB201719043D0 (en) Methods and compounds
GB201705133D0 (en) Method and use